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Abstract
From January 2004 to March 2007, 308 patients with clinically localized prostate cancer
were treated using iodine-125 (125I) seed implantation (permanent brachytherapy) at Okayama
University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. We evaluated
the treatment’s effi cacy and morbidity in 300 prostate cancer patients who were followed up for
more than 1 month after brachytherapy. Based on the National Comprehensive Cancer Network
(NCCN) guidelines, patients with a prostate volume of less than 40 ml in transrectal ultrasound
imaging were classifi ed as low or intermediate risk. The median patient age was 67 years (range
50 to 79 years), the median prostate-specific antigen (PSA) value before biopsy was 6.95 ng/ml
(range 1.13 to 24.7 ng/ml), and the median prostate volume was 24.33 ml (range 9.3 to 41.76 ml).
The median follow-up was 18 months (range 1 to 36 months) and the PSA levels decreased in
almost all patients after brachytherapy. Although 194 of 300 patients (64.7%) complained of diffi
culty in urination, pollakisuria/urgency, miction pain, and/or urinary incontinence, all of which
might be associated with radiation prostatitis during the fi rst month after brachytherapy, these
symptoms gradually improved. 125I seed implantation brachytherapy is safe and eff ective for
localized prostate cancer within short-term follow up.
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bidity
Iodine-125 Seed Implantation (Permanent Brachytherapy) 
for Clinically Localized Prostate Cancer
Shin Ebaraa,  Yoshihisa Katayamab,  Ryuta Tanimotoa,  Kohei Edamuraa,  
Hiroyuki Nosea,  Daisuke Manabea,  Tomoko Kobayashia,  Yasuyuki Kobayashia,  
Makoto Kobukea,  Mitsuhiro Takemotob,  Takashi Saikaa＊,  
Yasutomo Nasua,  Susumu Kanazawab,  and Hiromi Kumona
Departments of aUrology,  and bRadiology,  Okayama University Graduate School of Medicine,  
Dentistry and Pharmaceutical Sciences,  Okayama 700ﾝ8558,  Japan
n the past decade,  brachytherapy has been 
added to the armamentarium for the treatment 
of localized prostate cancer by the technical develop-
ment of transrectal ultrasound-guided transperineal 
seed implantation.  In July 2003,  the Japanese govern-
ment legalized the use of iodine-125 (125I) seed source.  
From January 2004 through February 2007,  300 
patients with clinically localized prostate cancer were 
treated with permanent brachytherapy by using 125I 
seed at our institution.  In this study,  we evaluated the 
eﬃ  cacy and morbidity of 300 localized prostate cancer 
patients who were followed up for more than 1 month 
after 125I seed implantation brachytherapy.
Materials and Methods
　 Treatment criteria. From January 2004 
through February 2007,  300 patients with clinically 
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localized prostate cancer were treated using 125I Seed 
implantation (permanent brachytherapy) at Okayama 
University Graduate School of Medicine,  Dentistry 
and Pharmaceutical Sciences.  Based on the National 
Comprehensive Cancer Network (NCCN) guidelines,  
we deﬁ ned the indications for brachytherapy as low-
risk group (PSA＜10 ng/ml and Gleason score ≦6 
and ≦T2a) or intermediate-risk group (PSA: 10ﾝ20 
and/or Gleason score 7 and/or T2b-T2c).
　 Pre-planning. Pre-planning is an outpatient 
procedure usually performed 1 month before seed 
implantation.  During the pre-planning,  transrectal 
ultrasound (TRUS),  a volumetric study of the pros-
tate gland was performed with the patients in the 
dorsal lithotomy position; the prostate gland was 
scanned at 5-mm intervals from the proximal seminal 
vesicles/base of the prostate gland to the apex using a 
biplanar ultrasound probe (ProSound SSD-5500,  
Aloka,  Tokyo,  Japan).  The captured images were 
digitized with a planning computer (Fig.  1).  The 
treatment planning was performed using the brachy-
therapy planning system VariSeed 7.1 (Varian 
Medical Systems,  Palo Alto,  CA,  USA) to calculate 
the well-designed dose volume histogram (DVH).  The 
gross target volume (GTV) was deﬁ ned as the prostate 
itself visualized on the TRUS images.  The planning 
target volume (PTV) was determined from the GTV 
plus a treatment margin of 3 mm in the lateral direc-
tion.  We set the treated volume to include the PTV 
within the prescribed isodose (145 Gy),  using a modi-
ﬁ ed peripheral loading technique.
　 Neoadjuvant hormonal therapy. In cases 
where prostate volume was over 40 ml or where ade-
quate dose volume histogram could not be calculated 
in pre-planning,  luteinizing hormone-releasing hor-
mone (LH-RH) agonist was administered for periods of 
3ﾝ6 months to reduce prostate volume.
　 Seed implantation. The seed implantation was 
performed under spinal anesthesia,  with the patient in 
the extended lithotomy position,  similar to the posi-
tion in pre-planning.  A Mick applicator (Mick Radio-
Nuclear Instruments,  Mount Vernon,  NY,  USA) was 
used to deposit the seeds.  The activity of the 125I seed 
source was 0.33 mCi/seed.
　 PSA evaluation and morbidity. All patients 
were followed up at 1 month and every 3 months in the 
ﬁ rst year after brachytherapy and every 6 months 
thereafter.  Clinical follow-up was started from the day 
of brachytherapy.  PSA was evaluated and urinary 
morbidity (diﬃ  culty in urination,  pollakisuria/
urgency,  miction pain,  and urinary incontinence) was 
recorded at each visit,  according to the National 
Cancer Institute common terminology criteria for 
adverse events version 3.0 (NCI-CTCAE v3.0).
　 Statistical analysis. Statistical analysis for 
diﬀ erences in prostate volume reduction after LH-RH 
agonist was performed using Fisher’s test using 
StatView J5.0 (SAS Institute,  Cary,  NC,  USA).  
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Fig. 1　　Transrectal ultrasound images in pre-planning study｡
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Diﬀ erences were regarded as statistically signiﬁ cant 
at p values less than 0.05.
Results
　 The patients’ clinical characteristics are shown in 
Table 1.  Of the 300 patients,  155 were placed into 
the low-risk group and 127 into the intermediate-risk 
group.  The median age was 67 years (range 50 to 79 
years),  the median PSA value before biopsy was 
6.95 ng/ml (range 1.13 to 24.7 ng/ml),  and the median 
prostate volume was 24.33 ml (range 9.3 to 41.76 ml).  
Of the 129 patients receiving hormonal therapy,  56 
received LH-RH agonist to reduce volume and subse-
quently experienced a 31.2ｵ reduction (Fig. 
2; reduction from 37.0±6.67 to 25.59±5.41 ml,  p＜
0.0001).  The median follow-up was 18 months (range 
1 to 36 months),  and the PSA levels gradually 
decreased after brachytherapy (Fig.  3).  The average 
PSA level was 0.57±0.38 ng/ml in the low-risk group 
and 0.78±0.41 ng/ml in the intermediate-risk group 
at 30 months after brachytherapy.  Although 194 of 
the 300 patients (64.7ｵ) complained of diﬃ  culty in 
urination,  pollakisuria/urgency,  miction pain,  and/or 
urinary incontinence,  all of which might be associated 
with radiation prostatitis during the ﬁ rst month after 
brachytherapy (Fig.  4).  Most urinary symptoms were 
generally grade 1 according to NCI-CTCAE version 
3.0,  and the degree of these symptoms gradually 
improved.  During the follow-up,  2 patients developed 
urinary obstruction requiring catheterization.  One 
patient improved gradually after receiving medication 
with an alpha-blocker,  the other still required cathe-
terization 11 months after brachytherapy.
Discussion
　 Prostate brachytherapy has been increasingly uti-
lized as the deﬁ nitive treatment for clinically localized 
prostate cancer.  The results of prostate brachyther-
apy have been reported to be as favorable as the those 
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Fig｡ 2　　Comparison of prostate volume pre and post hormonal 
therapy (p＜0.0001)｡
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Fig. 3　　PSA response after brachytherapy｡
Table 1　　Classiﬁ cation of patients
Age : 50－79 y｡o (median: 67 y｡o)
PSA (diagnosed) : 1.13－24.7 ng/ml (median: 6.95 ng/ml)
Prostate volume : 9.3－41.76 ml (median: 24.33 ml)
Follow-up : 1－36 month (median: 18 month)
Hormonal Tx No : 171 pts
Yes : 129 pts
PSA
　≦10 ng/ml : 235 pts
　10ﾝ20 ng/ml :  59 pts
　≧20 ng/ml :  6 pts
Gleason score
　≦6 : 188 pts
　＝7 : 100 pts
　≧8 :  12 pts
pts: patients
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for the most positive radical prostatectomy series,  
with lower incidences of urinary incontinence and 
sexual dysfunction [1ﾝ4].  Based on NCCN guidelines,  
localized prostate cancer was classiﬁ ed into 3 
groups: 1) Low-risk group (PSA＜10 ng/ml and 
Gleason score ≦6 and ≦T2a); 2) Intermediate-risk 
group (PSA: 10ﾝ20 and/or Gleason score ＝7 and/
or T2b-T2c); 3) High-risk group (PSA:＞20 ng/ml 
and/or Gleason score ≧8 and/or ≧T3a).  The 
guidelines recommend that seed implantation mono-
therapy is indicated for the low-risk group.  On the 
other hand,  the high-risk group should be treated with 
a combination of brachytherapy and external beam 
radiation therapy.  Either brachytherapy alone or in 
combination with external beam radiation therapy is 
indicated for the intermediate-risk group,  according 
to percentage of positive cores in the prostate biopsy 
cancer.
　 In Japan,  the use of 125I seed source was legalized 
in July 2003.  Japanese guidelines for the safe admin-
istration of I-125 brachytherapy demonstrated that the 
radioactivity in the prostate gland after brachytherapy 
might be within 1,300 MBq,  which would indicate that 
a large prostate volume (over 40 ml) might contra-
indicate brachytherapy as a monotherapy,  and that an 
administration of neoadjuvant ADT should be consid-
ered.  Wilson et al.  reported that neoadjuvant ADT is 
useful in decreasing the size of prostates greater than 
50 to 60 ml in volume and in improving the dosimetry 
and technical feasibility of brachytherapy [5].  In our 
study,  the administration of LH-RH agonist mono-
therapy reduced prostate volume by 31.2ｵ.
　 Stone et al.  reported a signiﬁ cant increase in uri-
nary symptoms and bother scores,  which peaked at 6 
months and persisted for 2 to 3 years after brachy-
therapy [6].  These urinary symptoms might be asso-
ciated with radiation prostatitis,  and our data also 
demonstrated that short-term urinary morbidity,  
including diﬃ  culty in urination,  pollakisuria/urgency,  
miction pain,  and/or urinary incontinence,  peaked at 
1 month after brachytherapy.  Most urinary symptoms 
were generally grade 1 according to NCI-CTCAE 
version 3.0,  except for 2 patients who developed uri-
nary retention (grade 3 morbidity).  One patient still 
requires catheterization,  and medications (alpha-
blockers and nonsteroidal anti-inﬂ ammatory drugs) 
have not relieved this patient’s urinary retention .  In 
this case,  trans-urethral resection of the prostate 
(TUR-p) may be required in the future.
　 Based on these recommendations and results,  our 
current criteria for brachytherapy are shown in Fig.  
5,  Although patients hope brachytherapy will reduce 
morbidity and shorten the hospital stay,  we must con-
sider their clinical factors,  including PSA,  Gleason 
score,  age,  and complications.  Our indications for this 
procedure are low or intermediate risk and prostate 
volume less than 30 ml by trans-abdominal ultrasound 
imaging.  If these factors are present,  pre-planning is 
performed.  If adequate DVH is found,  brachytherpay 
alone is chosen.  If prostate volume is over 40 ml or 
the adequacy of DVH cannot be evaluated,  LH-RH 
agonist is administered for 3 to 6 months.
　 Serum PSA values have been reported to gradually 
decline after brachytherapy [7].  Previous studies 
have established that median PSA nadir levels were 
0.2ﾝ0.5 ng/ml [7,  8] and continue to decrease for at 
least 4ﾝ5 years after brachytherapy [9,  10].  Our 
data indicated that median PSA levels were 0.57 ng/
ml in the low-risk group and 0.78 ng/ml in the inter-
mediate-risk group at 30 months after brachytherapy.  
Though the PSA levels gradually and satisfactorily 
decreased,  it might be too early to evaluate the PSA 
nadir and eﬃ  cacy of brachytherapy.
　 Conclusion. 125I seed implantation brachyther-
apy is safe and eﬀ ective for examining short-term 
outcomes of localized prostate cancer.  LH-RH agonist 
administration reduced prostrate volume.  Further 
follow-up is needed to evaluate the eﬃ  cacy and late-
term morbidity of brachytherapy.
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Fig｡ 5　　Current patient selection criteria (Okayama Univ.)
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